Revenue
2022
2023
2024
2025
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — | — | — | — |
| Research & development | $142.7M | $97.2M | $55.4M | $39.3M | $32.5M | $21.4M | $11.7M | $4.5M |
| Operating expenses | $172.2M | $125.1M | $74.7M | $54.1M | $46.3M | $33.8M | $18.7M | $6.2M |
| Operating income | −$172.2M | −$125.1M | −$74.7M | −$54.1M | −$46.3M | −$33.8M | −$18.7M | −$6.2M |
| EBITDA | −$170.6M | −$120.3M | −$73.2M | −$53.0M | −$45.6M | −$33.5M | −$18.6M | −$6.2M |
| Net income | −$167.9M | −$115.9M | −$67.7M | −$53.0M | −$46.3M | −$33.3M | −$16.9M | −$12.2M |
| Basic EPSper basic share | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
| Diluted EPSper diluted share | -$2.10 | -$2.34 | -$1.65 | -$1.81 | -$1.80 | -$1.44 | -$4.07 | -$6.87 |
Reported shareholders
| Holder | % owned |
|---|---|
JENNISON ASSOCIATES LLC | 11.94%20.03M shares |
T. Rowe Price Investment Management, Inc. | 11.25%18.87M shares |
Bain Capital Life Sciences Investors, LLC | 10.28%17.24M shares |
BlackRock, Inc. | 6.41%10.75M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.47%9.17M shares |
STATE STREET CORP | 4.67%7.84M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.31%7.23M shares |
Cormorant Asset Management, LP | 2.98%5M shares |
PRICE T ROWE ASSOCIATES INC /MD/ | 2.63%4.42M shares |
Woodline Partners LP | 2.50%4.2M shares |
NORGES BANK | 2.45%4.11M shares |
Opaleye Management Inc. | 2.30%3.86M shares |
CITADEL ADVISORS LLC | 2.10%3.52M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.06%3.46M shares |
FRANKLIN RESOURCES INC | 1.44%2.41M shares |
GOLDMAN SACHS GROUP INC | 1.32%2.21M shares |
MILLENNIUM MANAGEMENT LLC | 1.23%2.07M shares |
CANTOR FITZGERALD, L. P. | 0.95%1.6M shares |
MARSHALL WACE, LLP | 0.93%1.57M shares |
RENAISSANCE TECHNOLOGIES LLC | 0.92%1.54M shares |
Percentages use 167.73M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jan 21, 2026Form 4 | Chang David J.Chief Medical Officer | BuyCommon Stock | 8.8K | $2.26 | $19.9K | 8.8K |
| Jan 21, 2026Form 4 | Binder GwendolynPresident, Science & Tech. | BuyCommon Stock | 11.3K | $2.19 | $24.8K | 31.3K |
| Jan 21, 2026Form 4 | Tomasello ShawnDirector | BuyCommon Stock · indirect | 22.7K | $2.21 | $50.2K | 22.7K |
| Jan 21, 2026Form 4 | Gavel SteveChief Commercial Officer | BuyCommon Stock | 22.2K | $2.27 | $50.3K | 22.2K |
| Jan 21, 2026Form 4 | Bollard CatherineDirector | BuyCommon Stock | 4.4K | $2.27 | $10.0K | 5.4K |